is...optimistic for the future of CNS conditions thanks to Anavex Life Sciences.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would love to see the ultimate constriction on those shorts!
Listening to my Mom describe many of her friends’ families saying they’d opt for anything rather than continuing to see declines is just mortifying. Hopefully 2-73 and 3-71 are expedited, because their SAFETY along with their EFFICACY are top notch.
Pity those recipients of Lecanemab - LEQEMBI who will die because of the shady relationships between Biogen/Easai and certain FDA members trumped safety.
Changing the drug’s name to avoid negative associations is a thug maneuver.
“MONO-STYLE” for sure!!!
Added more shares. DCA up, but no worries.
A year from now $8 in the rear view mirror looks like leaving BFE for a national park.
Got another stink bid buy order in for $7.
“There comes a point where we need to stop just pulling people out of the river. We need to go upstream and find out why they're falling in.” - Desmond Tutu
Anavex Life Sciences takes the more proactive approach by addressing the upstream treatment and champions early detection to prevent serious illness. This was a managerial decision early on, and Dr. Christopher Missling has handled matters well.
No need to pay heed to the FUDsters who flit about like so many botflies.
Possible chestnuts for warming by the fire?
Any data or findings concerning patients dosed back in 2015?
Admittedly, there was still the funk of Aricept associated with the initial study, but since then there’ve been patients who have been donepezil-naïve and blarcamesine-only. How are the 2016, 2017, 2018, 2019… cohort members doing?
I think there are likely to be some very good testimonials and human interest stories ready for airing.
Have ongoing interviews, checkups, and progress reports been compiled up to this point?
The cornucopia of CNS conditions is about to be addressed.
“Anavex has more than sufficient resources to complete its current trials: approximately $150 million in cash and cash equivalents…”
Considering the burn rate has been so minimal (extremely efficient use of resources), it’s not as if there’s any question of not completing any and all trials, whether ongoing, or scheduled.
The safety profile, efficacy, and involvement of transcriptomics analysis (RNAseq) have been executed very well.
As any long time shareholder of Anavex Life Sciences has noticed, the petty attacks (long haired doctor! printing company! not a real doctor! not a real banker! equivalent to coffee! bad math! goal posts! this quarter! that quarter! etc) are just that, petty.
SIGMACEPTOR is real as ‘phuq’ and patients have already benefited from its existence.
We’re in the catbird seat. PRÓST!
FUDdies get out of the way!
There are endoplasmic reticulum systems in need of restoration!
And Anavex has the small molecules to make that a reality.
Weekend data crushathon for Monday!
Some busy folks doing post-analysis right now.
https://79bcf7a1-8b8e-483b-b7cf-f5c5192a6d63.usrfiles.com/ugd/79bcf7_0f2d70718aec4c2a90a37e20a5d92c2f.pdf
Slide 28!
Sorry donepezil and lecanemab, but there’s a SAFE new standard of care available that provides positive results.
https://www.fda.gov/media/133660/download
602 4. Statistical considerations
603
604 A typical criterion for concluding that a trial is positive (showed an effect) is a p value of < 0.05
605 (two sided). A lower p value, for example, would often be expected for reliance on a single trial.
606 For a serious disease with no available therapy or a rare disease where sample size might be
607 limited, as discussed further below, a somewhat higher p value – if prespecified and
608 appropriately justified – might be acceptable.
It’s in the bag baby. And for multiple indications. CNS powerhouse pipeline!
Alzheimers, Parkinsons, Dementia, Rett, Fragile X, Angelman…
Yep. Big Pharma and WS KNOW who the next big dog is.
Central Neurological System homeostatic regulation for the win. AVXL!
https://multiplesclerosisnewstoday.com/news-posts/2020/01/08/anavex-life-sciences-issued-new-us-patent-for-anavex-2-73-treatment-of-neurodevelopmental-disorders-including-rett-syndrome-and-multiple-sclerosis/
Best part of blarcamesine/ANAVEX 2-73?
Not just a one-trick pony! AD, Rett Syndrome, Parkinsons, and other
CNS conditions are in the pipeline too. (More goodness, and 3-71 too!)
Fill the gap!
Why the lowball for such a splendid pipeline?
ANAVEX®2-73 treatment met the primary endpoints and reduced clinical decline on the global cognitive and functional scales over 48 weeks in the analysis of the Intent-to-treat (ITT) population.
Met primary AND secondary endpoints! And no brain bleeding.
Freaking Outstanding!
ANAVEX®2-73 demonstrated visible improvement in patients with Alzheimer’s disease. Patients treated with ANAVEX®2-73 were 84% more likely, to have improved cognition by ADAS-Cog score change of -0.50 points or better from baseline to end of treatment than patients on placebo, Odds Ratio = 1.84 (p = 0.015). On average, patients, who improved cognitively with ANAVEX®2-73 treatment, improved by ADAS-Cog cognition score of -4.03 points. ANAVEX®2-73 treatment was 167% more likely to improve function compared with placebo, at a clinically meaningful improvement of ADCS-ADL score change of +3.5 points or better, Odds Ratio = 2.67 (p=0.0255). This reflects a robust improved and clinically meaningful outcome in cognition and function from baseline.
Additionally, treatment with ANAVEX®2-73 statistically significantly reduced cognitive decline, measured with ADAS-Cog, compared to placebo at end of treatment by 45%, representing a treatment difference in mean score change of -1.85 points (p=0.033).
ANAVEX®2-73 treatment also met the secondary endpoint of reduction in clinical decline of cognition and function assessed by the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) compared to placebo, by a treatment difference in mean score change of -0.42 points (p=0.040), representing 27% reduction in the ITT population.
$160+ perhaps!
This was a year ago…
“Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.”
https://www.nytimes.com/2021/06/10/health/aduhelm-fda-resign-alzheimers.html
No safety concerns for Anavex Life Sciences, but Easai/Biogen have dumped vast sums of money into PR for BAN2401. Probably just to get out ahead of 2-73.
At least Blarcamesine has no history of the following…
“Around 40% of participants receiving the higher dosage of Aduhelm developed brain swelling or bleeding, and around 6% of high-dose participants stopped taking the drug due to side effects.Nov 29, 2021”
Time to replace ‘done zip pill’ with Blarcamesine!
New standard of care provided by Anavex Life Sciences.
No doubts about how safe and effective the Anavex product is vs. that other one with the scandalous history.
Biogen damage control. Spin it. SPIN IT!
Biogen brain hemorrhage article: https://www.science.org/content/article/second-death-linked-potential-antibody-treatment-alzheimer-s-disease
Blarcamesine and 3-71 for the win!
“brain bleed risks”/ Lecanemab not worth it
Blarcamesine for the win without hemorrhagic side effects.
“Giving Tuesday is less than 48 hours away! On November 29, thousands of supporters will donate gifts of every size to help Parkinson’s researchers accelerate our search for a cure. But you can get a head start today. Donate now and your donation will count toward the match.”
Think I’ll buy another 1000 shares of Anavex Life Sciences because 2-73 and 3-71 plus genetic markers are nailing it.
A-Damning-Fraudstain? Here’s how to prepare…
You KNOW that malignant shorty has been and is actively working against AVXL. For years now.
Have a purchase order ready at a lower price if he does release some defamatory hit piece prior to, or during CTAD.
Then you have that many more shares to watch climb to a higher price.
Well…plenty of other good things on the way!
Clofazimine, sold under the brand name Lamprene, is a medication used together with rifampicin and dapsone to treat leprosy. It is specifically used for multibacillary leprosy and erythema nodosum leprosum.
Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.
Dornase alfa is used to reduce the number of lung infections and to improve lung function in patients with cystic fibrosis.
Transforming growth factor-beta (TGFß) is a secreted cytokine, which intricately controls a plethora of physiological and pathological processes during development and carcinogenesis. TGFß exerts antiproliferative effects and functions as a tumor suppressor during early stages of tumorigenesis, whereas at later stages it functions as a tumor promoter aiding in metastatic progression through an autocrine TGFß loop. Intricate knowledge of TGFß signaling and its regulation are still evolving. In this review, we make an attempt to showcase the associated enigma of TGFß signaling in its dual functional role as tumor suppressor and metastatic promoter during early and late stages of carcinogenesis, respectively.
Technosphere® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulins
The Afrezza with Basal Combination (ABC) Study demonstrated similar glucose control between the three treatment groups; data to be presented and published in 2023
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
Just wish there were more options (LOCATIONS!) for receiving Novavax vaccines!
…and ‘Howe’! <3 <3 <3
Massive applause to building the dream team!
https://nymag.com/intelligencer/article/what-to-know-new-covid-variants-bq-1-bq-1-1-xbb-bf-7.html
Sure would be a massive positive to get Brilacidin into a usable form.
Looking forward to the MJFF’s newsletter when Blarcamesine is featured.
https://viewer.joomag.com/the-fox-focus-2022-fall-winter/0166691001665609927
https://clinicaltrials.gov/ct2/show/NCT03790709
https://clinicaltrials.gov/ct2/show/NCT04575259
https://clinicaltrials.gov/ct2/show/NCT04304482
Been patient since the share price was in the teens and up to forty cents. AVXL has come a long way with consistent results and findings as well as expanded uses/indications. From 2-73 to 3-71, it’s been a journey. Getting pretty excited for what’s to be revealed.
“In pre-clinical studies, Brilacidin shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited potent stand-alone efficacy against Cryptococcus neoformans.
These data suggest Brilacidin has potential as a novel antifungal agent.”
BRING IT TO MARKET!!!